Global Hypertension Market, By Type (Primary Hypertension, Secondary Hypertension, Others), Measurement Categories (Normal Blood Pressure, Elevated Blood Pressure, Stage 1 Hypertension, Stage 2 Hypertension, Others), Treatment (Medication, Additional Therapy, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Hypertension Market Analysis and Size
The global hypertension drug market growth is driven through primary factors i.e. increase in sudden incidences of hypertension worldwide, people affected by diabetes, improvement in technology, and growing aging population. In addition, rising expenditures on health, an increase in cardiovascular diseases, and growing tobacco users are fuelling the growth of the global market. According to WHO (World Health Organization), more than 1.13 billion people are suffering from hypertension globally, among them, only 1 in each 5 is cured or under control. WHO also states that in the 21st-century hypertension is one of the silent killers and one of the largest concerns of public health.
Data Bridge Market Research analyses that the hypertension market which was USD 31.76 billion in 2022, is expected to reach USD 43.18 billion by 2030, and is expected to undergo a CAGR of 4.00% during the forecast period of 2023 to 2030. “Hospitals” dominates the end user segment of the global hypertension market owing to the growing demand for drug. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Hypertension Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Type (Primary Hypertension, Secondary Hypertension, Others), Measurement Categories (Normal Blood Pressure, Elevated Blood Pressure, Stage 1 Hypertension, Stage 2 Hypertension, Others), Treatment (Medication, Additional Therapy, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd (Switzerland), Fresenius Kabi AG (Germany), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd. (India), Novartis AG (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Zydus Group (India), Pfizer Inc. (U.S.), Lupin (India), GSK Plc (U.K.), Glenmark Pharmaceuticals Inc. (India), Wockhardt (India)
|
|
Market Opportunities
|
|
Market Definition
Hypertension or elevated blood pressure that causes severe medical conditions significantly increases the risks of heart, brain, and kidney diseases. Blood pressure is denoted as two numbers: systolic blood pressure, which represents pressure in blood vessels when the heart contracts or beats, and diastolic blood pressure, which represents the pressure in the vessels when the heart rests between beats. The normal blood pressure is 120/80 mm Hg.
Global Hypertension Market Dynamics
Drivers
- Increase in Cardiovascular Diseases
According to the WHO, about 60% - 85% of the population have adopted a sedentary life. According to CDC, nearly 31 million adults aged over 50 years live a sedentary life, and only 1 out of 4 U.S. adults meet the appropriate need for physical activity. This boost the market growth.
- Rising FDA Approvals
The persistent product approvals are projected to boost market growth. For instance, in May 2022, Zydus Lifesciences Limited's subsidiary received tentative approval from the U.S. FDA to market Selexipag tablets which are used to treat pulmonary arterial hypertension (PAH) in adults. In February 2022, the FDA approved the Norliqva (amlodipine) oral solution to treat hypertension in adults and children six years or older to lower blood pressure and coronary artery disease.
- Rising Prevalence of Hypertension
As per the American College of Cardiology, older adults are mostly undertreated for high blood pressure, despite having the maximum incidence of hypertension and the highest risk of CV morbidity and mortality (B.P.). According to the National Health and Nutrition Examination Survey (NHANES) records in the U.S., hypertension affects 70% of persons over 65. As our population ages, this figure will continue to rise. This will create more opportunities for market growth as the demand for blockers increases.
Opportunity
- Increasing Demand for Retail Pharmacies
The rise in the number of hypertension drugs delivered through retail pharmacies and the rise in the number of retail pharmacies in highly developed countries can create opportunities for market growth. In addition, patients prefer retail pharmacies for purchasing drugs, as these are easily available such as increasing applications will create lucrative opportunities in the market, thereby supplementing the market growth.
Restraints/Challenges
- Lack of Awareness
Lack of awareness associated with using anti-hypertensive drugs among the population is one of the leading restraints in the global hypertension market. People are often ignorant about their health check-ups, particularly in developing nations, and aren't aware of the prevailing high blood pressure situation until they come across severe signs and symptoms.
-
Irregularity in Medicine Consumption
People diagnosed with high blood pressure don't stick to their medicinal drug timetable and stop taking medicine after 1-2 weeks until signs and symptoms return, thus posing a large challenge to the global hypertension market. For instance, BMC Research performed a survey that states that out of the overall 112 hypertensive subjects with stroke, most effective 17% of them had been adherent to antihypertensive medications. Lack of awareness and low adherence to the drugs can limit the growth of the global hypertension market.
This global hypertension market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hypertension market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In December 2021, Dr. Reddy's Laboratories launched Valsartan tablets in the United States for the treatment of high blood pressure and heart collapse. The U.S. Food and Drug Administration (USFDA) has approved Diovan's generic therapeutic substitute
Global Hypertension Market Scope
The global hypertension market is segmented on the basis of type, treatment, measurement categories, end-user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Primary Hypertension
- Secondary Hypertension
- Others
Treatment
- Medication
- Additional Therapy
- Others
Measurement Categories
- Normal Blood Pressure
- Elevated Blood Pressure
- Stage 1 Hypertension
- Stage 2 Hypertension
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Global Hypertension Market Analysis/Insights
The global hypertension market is analysed and market size insights and trends are provided by country, type, treatment, measurement categories, end-user and distribution channel as referenced above.
The countries covered in the global hypertension market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Asia-Pacific dominates the global hypertension market to grow during the forecast period due to the increased prevalence of hypertension diseases and the increasing geriatric population in the region.
North America has been witnessing positive growth in the global hypertension market due to the increased R&D activities in the industry and higher healthcare expenditure in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The global hypertension market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global hypertension market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global hypertension market. The data is available for historic period 2015-2021.
Competitive Landscape and Global Hypertension Market Share Analysis
The global hypertension market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global hypertension market.
Some of the major players operating in the global hypertension market are:
- F. Hoffmann-La Roche Ltd (Switzerland)
- Fresenius Kabi AG (Germany)
- Bayer AG (Germany)
- Sun Pharmaceutical Industries Ltd. (India)
- Novartis AG (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd (Israel)
- Zydus Group (India)
- Pfizer Inc. (U.S.)
- Lupin (India)
- GSK Plc. (U.K.)
- Glenmark Pharmaceuticals Inc. (India)
- Wockhardt (India)
SKU-